
The North Dakota Cancer Coalition is made up of partners from across the state who work together with the common goal of reducing the incidence and death of cancer among North Dakotans. North Dakota Cancer Coalition partners worked together to write North Dakota’s Cancer Control Plan.
Any organization or individual interested in working to reduce the incidence and death of cancer among North Dakotas may join the Coalition. As a North Dakota Cancer Coalition member, partners also have the option of receiving resources for their cancer prevention and control implementation efforts. Member dues are $50 per membership year beginning January 1, 2025.
Visit Our Sponsors
The appearance of hyperlinks does not constitute endorsement by the ND Cancer Coalition of this website, information, products or services contained therein.
Jazz Pharmaceuticals
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Deciphera
Fueled by our proprietary drug discovery platform, Deciphera’s mission is to discover, develop, and deliver important new medicines to patients for the treatment of cancer. We aim to provide novel treatments for patients through inhibition of protein kinases.
NeoGenomics Laboratories
When cancer leaves our customers and their patients in the dark, NeoGenomics is here to light the way. For over 20 years, we’ve built our business around complex cancer insights, uniquely positioned to help our partners break new ground as they navigate the increasingly complex disease landscape — allowing patients to arrive at transformative care plans that help save lives. Wherever you are on the cancer care continuum, our industry-leading testing and information solutions will guide you toward a brighter future in tackling cancer.
SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.
Servier Pharmaceuticals
Servier US, a commercial-stage, privately held pharmaceutical company, is a leader in oncology and is building up its neurology business, focused on addressing rare diseases and unmet patient needs with a commitment to delivering innovative therapies.
Tempus AI
AI-enabled precision medicine: Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.
Exact Sciences
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Takeda Oncology
At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We know that our mission is not a quick or simple one, but we are up for the task:
We aspire to cure cancer.